Key Takeaways
- Koppert secures five-year exclusive distribution rights for Amoéba’s biofungicide in 18 European countries and the U.S.
- Launch planned for early 2026 following EU Member States’ approval of the active substance
- Agreement covers vine and vegetable crops grown in greenhouses and open fields
- Potential expansion to Brazil and future co-development projects under discussion
- Strategic milestone reinforces both companies’ commitment to sustainable crop protection
Koppert and Amoéba Finalize Distribution Agreement for Microbiological Biofungicide
Koppert, a global biocontrol solutions provider, and Amoéba, a greentech company specializing in microbiological innovations, have signed a long-term commercial agreement for the distribution of a new biofungicide based on the amoeba Willaertia magna C2c Maky. The agreement was formalized on June 3, 2025, and follows the recent approval of Amoéba’s biocontrol active substance by EU Member States.
Under the agreement, Koppert will distribute the biofungicide under its own brand beginning in early 2026, targeting vines and vegetable crops across 18 European countries and the United States. The product is designed for both greenhouse and open-field applications.
Agreement Reflects Strategic Focus on Scalable, Sustainable Solutions
The biofungicide is derived from a lysate of Willaertia magna and is characterized as an environmentally friendly solution that combats a wide range of plant diseases. The agreement grants Koppert exclusive distribution rights for five years, with potential for further collaboration in Brazil pending market evaluation.
“This agreement marks a significant step forward in expanding our portfolio of innovative biological solutions,” said Martin Koppert, Chief Business Officer of Koppert. “This new biofungicide solution is an exciting addition that aligns perfectly with our mission.”
Future Collaboration on New Products and Production Planning
Koppert and Amoéba also plan to explore co-development opportunities for additional biofungicide applications for the crops covered under the agreement. The two companies will assess future production strategies based on operational feedback and expected commercial scale-up.
“Discussions over the last few months have been very fruitful,” said Jean-François Doucet, CEO of Amoéba. “We are delighted to have reached a mutually beneficial agreement. This once again demonstrates the potential of our biofungicide solution.”
Koppert & Amoéba: A Shared Vision for Advancing Sustainable Agriculture
The agreement signals a strategic step for Amoéba, which has invested years of research and development into its biocontrol platform. It also reinforces Koppert’s leadership in providing growers with biological alternatives to synthetic crop protection.
“We share many common values and the desire to offer healthy products to the agricultural world,” said Benoît Villers, Chairman of the Board of Directors at Amoéba. “This is a major step forward that now allows us to explore further commercial and industrial expansion.”
